4
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
6
Rare Diseases
across 17 areas
0
News (30d)
Quiet
Millendo Therapeutics, Inc. is a company with 4 orphan drug designations across 6 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Cushing syndrome | N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt | Des.TrialAppr. |
| Prader-Willi syndrome | synthetic cyclic 8 amino acid analog of human unacylated ghrelin | Des.TrialAppr. |
| Prader-Willi-like syndrome | synthetic cyclic 8 amino acid analog of human unacylated ghrelin | Des.TrialAppr. |
| Schaaf-Yang syndrome | synthetic cyclic 8 amino acid analog of human unacylated ghrelin | Des.TrialAppr. |
| adrenal cortex carcinoma | nevanimibe HCL | Des.TrialAppr. |
| congenital adrenal hyperplasia | nevanimibe HCL | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio